Nymox Pharmaceutical Corp. (NYMX) reported a third-quarter net loss of $1.36 million or $0.04 per share, compared to a loss of $1.32 million or $0.04 per share in the year ago quarter.
For the nine months ending September 30, 2009, Nymox reported a net loss of $3.59 million or $0.12 per share, compared to a loss of $3.71 million or $0.13 per share for the nine months ending September 30, 2008.
Net losses include stock compensation charges for the quarter of $322,808 in 2009 and $293,180 in 2008 and for the nine months of $881,344 in 2009 and $702,540 in 2008. The increase of the net loss for the quarter is mainly attributable to expenses relating to the launch of Phase 3 clinical trials for NX-1207.
The decrease in net losses for the nine months period is attributable to reduced general and administrative expenditures compared to 2008. Product sales amounted to $71,904 for the quarter and $248,471 for the nine months ending September 30, 2009, compared to $82,171 and $306,849 for the same periods in 2008 due to a decrease in sales attributable to the current economic slowdown.
For comments and feedback: editorial@rttnews.com